Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 Debt-to-Equity is 0.26 as of Jun. 2026, which is 2500% above its 10-year median of 0.01. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, VISEN Pharmaceuticals ranks better than 56.23% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for VISEN Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
FRA:T06'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.26
Current: 0.26
During the past 4 years, the highest Debt-to-Equity Ratio of VISEN Pharmaceuticals was 0.26. The lowest was 0.00. And the median was 0.01.
FRA:T06's Debt-to-Equity is ranked better than 56.23% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:T06: 0.26
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
VISEN Pharmaceuticals Debt-to-Equity Related Terms
VISEN Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (FRA:T06) has a Debt-to-Equity of 0.26 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VISEN Pharmaceuticals and its competitors. This is 2500% above median its historical median of 0.01. According to the industry distribution chart, VISEN Pharmaceuticals ranks #355 out of 811 companies in the Drug Manufacturers industry, placing it in the top 43.8%.
Is VISEN Pharmaceuticals' Debt-to-Equity too high?
VISEN Pharmaceuticals' current Debt-to-Equity of 0.26 is 2500% above median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. VISEN Pharmaceuticals' value of 0.26 is 3.7% below this industry median. Based on the distribution chart, VISEN Pharmaceuticals ranks #355 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #355 out of 811 companies for Debt-to-Equity. This puts VISEN Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.27. VISEN Pharmaceuticals' value of 0.26 is 3.7% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.27, VISEN Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VISEN Pharmaceuticals's current Debt-to-Equity of 0.26 is 3.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current Debt-to-Equity is 0.26, which is 2500% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Debt-to-Equity of 0.26. The current Debt-to-Equity is 0.26, which is 2500% above median its 10-year median of 0.01 and 3.7% below the Drug Manufacturers industry median of 0.27. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Debt-to-Equity is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
